{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:58:31Z","timestamp":1778767111816,"version":"3.51.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s11033-020-06093-z","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T17:03:20Z","timestamp":1615482200000},"page":"2035-2046","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Influence of genetic polymorphisms in glutathione-S-transferases gene in response to imatinib among Brazilian patients with chronic myeloid leukemia"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4565-5516","authenticated-orcid":false,"given":"Kezia Aguiar","family":"Delmond","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1778-0299","authenticated-orcid":false,"given":"Hugo","family":"Delleon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8548-9946","authenticated-orcid":false,"given":"Rebeca Mota","family":"Goveia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9960-1417","authenticated-orcid":false,"given":"Thallita Monteiro","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davi Carvalho","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7389-6125","authenticated-orcid":false,"given":"Francyelli","family":"Mello-Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8281-7334","authenticated-orcid":false,"given":"Angela Adamski da Silva","family":"Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0362-0988","authenticated-orcid":false,"given":"Daniela de Melo e","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8739-8327","authenticated-orcid":false,"given":"Adriana do Prado","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0829-3157","authenticated-orcid":false,"given":"Renato Sampaio","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Eduardo","family":"Anuncia\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4143-9007","authenticated-orcid":false,"given":"Elis\u00e2ngela","family":"Silveira-Lacerda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"key":"6093_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7\u201330. https:\/\/doi.org\/10.3322\/caac.21332","journal-title":"CA Cancer J Clin"},{"key":"6093_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) A new consistent chromossomal abnormality in chronic myelogenous leukaemia indetified by quinacrine fluorescence and giemsa staining. Nature 243:290\u2013293. https:\/\/doi.org\/10.1038\/243290a0","journal-title":"Nature"},{"key":"6093_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/ajh.34","volume":"89","author":"EJ Jabbour","year":"2014","unstructured":"Jabbour EJ, Kantarjian H (2014) CME Information: chronic myeloid leukemia: 2014 update. Am J Hematol 89:547\u2013556. https:\/\/doi.org\/10.1002\/ajh.34","journal-title":"Am J Hematol"},{"key":"6093_CR4","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","volume":"18","author":"A Hochhaus","year":"2004","unstructured":"Hochhaus A, PLR (2004) Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance \u00b4. Leukemia 18:1321\u20131331. https:\/\/doi.org\/10.1038\/sj.leu.2403426","journal-title":"Leukemia"},{"key":"6093_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1084\/jem.20062335","volume":"204","author":"RA Van Etten","year":"2007","unstructured":"Van Etten RA (2007) Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J Exp Med 204:461\u2013465. https:\/\/doi.org\/10.1084\/jem.20062335","journal-title":"J Exp Med"},{"key":"6093_CR6","first-page":"433","volume":"1","author":"P Valent","year":"2007","unstructured":"Valent P (2007) Imatinib-resistant chronic myeloid leukemia ( CML ): current concepts on pathogenesis and new emerging pharmacologic approaches. Biol Targets Ther 1:433\u2013448","journal-title":"Biol Targets Ther"},{"key":"6093_CR7","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1182\/blood.V97.8.2440","volume":"97","author":"K Okuda","year":"2001","unstructured":"Okuda K, Weisberg E, Gilliland DG, Griffin JD (2001) ARG tyrosine kinase activity is inhibited by STI571. Blood J 97:2440\u20132449","journal-title":"Blood J"},{"key":"6093_CR8","first-page":"8","volume":"76","author":"R Frazer","year":"2007","unstructured":"Frazer R, Irvine AE, McMullin MF (2007) Chronic myeloid leukaemia in The 21st century. Ulster Med J 76:8\u201317","journal-title":"Ulster Med J"},{"key":"6093_CR9","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1634\/theoncologist.2013-0191","volume":"18","author":"ET Liu","year":"2013","unstructured":"Liu ET, Johnston PG (2013) Personalized medicine: does the molecular suit fit? Oncologist 18:653\u2013654. https:\/\/doi.org\/10.1634\/theoncologist.2013-0191","journal-title":"Oncologist"},{"key":"6093_CR10","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, M\u00fcller MC, Hehlmann R et al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26:2096\u20132102. https:\/\/doi.org\/10.1038\/leu.2012.85","journal-title":"Leukemia"},{"key":"6093_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/306239a0","volume":"1","author":"LA Pray","year":"2008","unstructured":"Pray LA (2008) Gleevec: the breakthrough in cancer treatment. Nat Educ 1:37. https:\/\/doi.org\/10.1038\/306239a0","journal-title":"Nat Educ"},{"key":"6093_CR12","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.leukres.2013.04.003","volume":"37","author":"S Francis","year":"2013","unstructured":"Francis S, Lucas C, Lane S et al (2013) A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia. Leuk Res 37:752\u2013758. https:\/\/doi.org\/10.1016\/j.leukres.2013.04.003","journal-title":"Leuk Res"},{"key":"6093_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12032-014-0047-z","volume":"7","author":"Y Kassogue","year":"2014","unstructured":"Kassogue Y, Quachouh M, Dehbi H et al (2014) Effect of interaction of glutathione S -transferases ( T1 and M1 ) on the hematologic and cytogenetic responses in chronic myeloid leukemia patients treated with imatinib. Med Oncol 7:31\u201347. https:\/\/doi.org\/10.1007\/s12032-014-0047-z","journal-title":"Med Oncol"},{"key":"6093_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2015.05.009","volume":"152","author":"T Terada","year":"2015","unstructured":"Terada T, Noda S, Inui K-I (2015) Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther 152:125\u2013134. https:\/\/doi.org\/10.1016\/j.pharmthera.2015.05.009","journal-title":"Pharmacol Ther"},{"key":"6093_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ejphar.2015.08.034","volume":"765","author":"S Vaidya","year":"2015","unstructured":"Vaidya S, Ghosh K, Shanmukhaiah CBRV (2015) Genetic variations of hOCT1 gene and CYP3A4 \/ A5 genes and their association with imatinib response in Chronic Myeloid Leukemia. Eur J Pharmacol 765:124\u2013130. https:\/\/doi.org\/10.1016\/j.ejphar.2015.08.034","journal-title":"Eur J Pharmacol"},{"key":"6093_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.canep.2016.07.008","volume":"44","author":"N Weich","year":"2016","unstructured":"Weich N, Ferri C, Moiraghi B et al (2016) GSTM1 and GSTP1 , but not GSTT1 genetic polymorphisms are associated with chronic myeloid leukemia risk and treatment response. Cancer Epidemiol 44:16\u201321. https:\/\/doi.org\/10.1016\/j.canep.2016.07.008","journal-title":"Cancer Epidemiol"},{"key":"6093_CR17","doi-asserted-by":"publisher","unstructured":"Valdes R, Yin D (Tyler) (2016) Fundamentals of pharmacogenetics in personalized, precision medicine. Clin Lab Med 36:447\u2013459. https:\/\/doi.org\/10.1016\/j.cll.2016.05.006","DOI":"10.1016\/j.cll.2016.05.006"},{"key":"6093_CR18","doi-asserted-by":"publisher","first-page":"7369","DOI":"10.1038\/sj.onc.1206940","volume":"22","author":"DM Townsend","year":"2003","unstructured":"Townsend DM, Tew KD (2003) The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22:7369\u20137375. https:\/\/doi.org\/10.1038\/sj.onc.1206940","journal-title":"Oncogene"},{"key":"6093_CR19","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/sj.onc.1209373","volume":"25","author":"CC Mcllwain","year":"2006","unstructured":"Mcllwain CC, Townsend DM, Tew KD (2006) Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25:1639\u20131648. https:\/\/doi.org\/10.1038\/sj.onc.1209373","journal-title":"Oncogene"},{"key":"6093_CR20","first-page":"12","volume":"138","author":"M Taspinar","year":"2008","unstructured":"Taspinar M, Aydos S, Comez O et al (2008) CYP1A1 , GST gene polymorphisms and risk of chronic myeloid leukaemia. Swiss Med Wkly 138:12\u201318 https:\/\/doi.org\/2008\/01\/smw-12036","journal-title":"Swiss Med Wkly"},{"key":"6093_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s13277-014-1810-7","volume":"78","author":"LA Hegazy","year":"2010","unstructured":"Hegazy LA, Mohamad Nohair SAAAE-A (2010) Glutathione S transferase T1 and M1 gene polymorphisms and risk of myeloid leukemias. Med J Cairo Univ 78:67\u201375. https:\/\/doi.org\/10.1007\/s13277-014-1810-7","journal-title":"Med J Cairo Univ"},{"key":"6093_CR22","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.7314\/APJCP.2013.14.6.3861","volume":"14","author":"L Zhou","year":"2013","unstructured":"Zhou L, Zhu Y-Y, Zhang X-D et al (2013) Risk effects of GST gene polymorphisms in patients with acute myeloid leukemia: a prospective study. Asian Pacific J Cancer Prev 14:3861\u20133864. https:\/\/doi.org\/10.7314\/APJCP.2013.14.6.3861","journal-title":"Asian Pacific J Cancer Prev"},{"key":"6093_CR23","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1007\/s13277-014-1810-7","volume":"35","author":"H He","year":"2014","unstructured":"He H, Zhang X, Sun J et al (2014) Glutathione S-transferase gene polymorphisms and susceptibility to chronic myeloid leukemia. Tumor Biol 35:6119\u20136125. https:\/\/doi.org\/10.1007\/s13277-014-1810-7","journal-title":"Tumor Biol"},{"key":"6093_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40064-015-0966-y","volume":"4","author":"Y Kassogue","year":"2015","unstructured":"Kassogue Y, Dehbi H, Quachouh M et al (2015) Association of glutathione S-transferase (GSTM1 and GSTT1) genes with chronic myeloid leukemia. Springerplus 4:3\u20137. https:\/\/doi.org\/10.1186\/s40064-015-0966-y","journal-title":"Springerplus"},{"key":"6093_CR25","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/clpt.2014.176","volume":"96","author":"A Davies","year":"2014","unstructured":"Davies A, Giannoudis A, Zhang JE et al (2014) Dual glutathione-S-transferase-\u03b81 and -\u03bc1 gene deletions determine imatinib failure in chronic myeloid leukemia. Clin Pharmacol Ther 96:694\u2013703. https:\/\/doi.org\/10.1038\/clpt.2014.176","journal-title":"Clin Pharmacol Ther"},{"key":"6093_CR26","doi-asserted-by":"publisher","unstructured":"Al-achkar W, Moassass F, Aroutiounian R (2017) Effect of Glutathione S-transferase mu 1 (GSTM1) gene polymorphism on chronic myeloid leukemia risk and Imatinib treatment response. Meta Gene 1. https:\/\/doi.org\/10.1016\/j.mgene.2017.02.006","DOI":"10.1016\/j.mgene.2017.02.006"},{"issue":"7","key":"6093_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.717","volume":"7","author":"G Rostami","year":"2019","unstructured":"Rostami G (2019) Influence of glutathione S - transferases ( GSTM1 , GSTT1 , and GSTP1 ) genetic polymorphisms and smoking on susceptibility risk of chronic myeloid leukemia and treatment response. Mol Genet Genomic Med 7(7):e00717. https:\/\/doi.org\/10.1002\/mgg3.717","journal-title":"Mol Genet Genomic Med"},{"issue":"1","key":"6093_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11523-020-00696-z","volume":"15","author":"N Lee","year":"2020","unstructured":"Lee N, Min S, Jeong P et al (2020) Association between glutathione - S - transferase gene polymorphisms and responses to tyrosine kinase inhibitor treatment in patients with chronic myeloid leukemia: a meta - analysis. Target Oncol 15(1):47\u201354. https:\/\/doi.org\/10.1007\/s11523-020-00696-z","journal-title":"Target Oncol"},{"key":"6093_CR29","volume-title":"Population, ethnicity, and nation-building","author":"TE Skidmore","year":"2019","unstructured":"Skidmore TE (2019) Fact and myth: discovering a racial problem in Brazil. In: Population, ethnicity, and nation-building"},{"key":"6093_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1590\/S1415-47572008000100008","volume":"31","author":"CL Souza","year":"2008","unstructured":"Souza CL, Barbosa CG, de Moura Neto JP et al (2008) Polymorphisms in the glutathione S-transferase theta and mu genes and susceptibility to myeloid leukemia in Brazilian patients. Genet Mol Biol 31:39\u201341. https:\/\/doi.org\/10.1590\/S1415-47572008000100008","journal-title":"Genet Mol Biol"},{"key":"6093_CR31","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.4238\/2012.April.19.6","volume":"11","author":"GS Lordelo","year":"2012","unstructured":"Lordelo GS, Akimoto AK, Alves PCZ (2012) Association between methylene tetrahydrofolate reductase and glutathione S-transferase M1 gene polymorphisms and chronic myeloid leukemia in a Brazilian population. Genet Mol Res 11:1013\u20131026","journal-title":"Genet Mol Res"},{"key":"6093_CR32","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.bjhh.2017.04.007","volume":"39","author":"AL Vieira-Mion","year":"2017","unstructured":"Vieira-Mion AL, Pereira NF, Funke VAM, Pasquini R (2017) Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia. Rev Bras Hematol Hemoter 39:210\u2013215. https:\/\/doi.org\/10.1016\/j.bjhh.2017.04.007","journal-title":"Rev Bras Hematol Hemoter"},{"key":"6093_CR33","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) Review Article European LeukemiaNet recommendations for the management of chronic myeloid leukemia\u00a0: 2013. Blood J 122:872\u2013885. https:\/\/doi.org\/10.1182\/blood-2013-05-501569","journal-title":"Blood J"},{"key":"6093_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0076262","volume":"8","author":"DS Pinheiro","year":"2013","unstructured":"Pinheiro DS, Rocha Filho CR, Mundim CA et al (2013) Evaluation of glutathione S-transferase GSTM1 and GSTT1 deletion polymorphisms on Type-2 diabetes mellitus risk. PLoS One 8:1\u20135. https:\/\/doi.org\/10.1371\/journal.pone.0076262","journal-title":"PLoS One"},{"key":"6093_CR35","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2353\/jmoldx.2010.090076","volume":"12","author":"F Mar\u00edn","year":"2010","unstructured":"Mar\u00edn F, Garcia N, Munoz X, Capella G, Gonz\u00e1lez CA, Agudo A, Sala N (2010) Simultaneous genotyping of GSTT1 and GSTM1 null polymorphisms by melting curve analysis in presence of SYBR green I Fa. J Mol Diagnosis 12:300\u2013304. https:\/\/doi.org\/10.2353\/jmoldx.2010.090076","journal-title":"J Mol Diagnosis"},{"key":"6093_CR36","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1093\/carcin\/18.4.641","volume":"18","author":"LW Harries","year":"1997","unstructured":"Harries LW, Stubbins MJ, Forman D et al (1997) Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder , testicular and prostate cancer. Carcinogenesis 18:641\u2013644. https:\/\/doi.org\/10.1093\/carcin\/18.4.641","journal-title":"Carcinogenesis"},{"issue":"1","key":"6093_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/bioinformatics\/19.1.149","volume":"19","author":"S Purcell","year":"2003","unstructured":"Purcell S, Cherny SS, Sham PC (2003) Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics. 19(1):149\u2013150. https:\/\/doi.org\/10.1093\/bioinformatics\/19.1.149","journal-title":"Bioinformatics."},{"key":"6093_CR38","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1124\/dmd.105.004283.1998","volume":"33","author":"H-P Gschwind","year":"2005","unstructured":"Gschwind H-P, Pfaar U, Waldmeier F et al (2005) Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 33:1503\u20131512. https:\/\/doi.org\/10.1124\/dmd.105.004283.1998","journal-title":"Drug Metab Dispos"},{"key":"6093_CR39","doi-asserted-by":"publisher","first-page":"12749","DOI":"10.1074\/jbc.M005561200","volume":"276","author":"SG Cho","year":"2001","unstructured":"Cho SG, Lee YH, Park HS et al (2001) Glutathione S-transferase Mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1. J Biol Chem 276:12749\u201312755. https:\/\/doi.org\/10.1074\/jbc.M005561200","journal-title":"J Biol Chem"},{"key":"6093_CR40","doi-asserted-by":"publisher","first-page":"8608","DOI":"10.1074\/jbc.M308613200","volume":"279","author":"L Gate","year":"2004","unstructured":"Gate L, Majumdar RS, Lunk A, Tew KD (2004) Increased myeloproliferation in glutathione S-transferase -deficient mice is associated with a deregulation of JNK and Janus kinase\/STAT pathways. J Biol Chem 279:8608\u20138616. https:\/\/doi.org\/10.1074\/jbc.M308613200","journal-title":"J Biol Chem"},{"key":"6093_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ajh.24249","volume":"91","author":"E Jabbour","year":"2016","unstructured":"Jabbour E (2016) Chronic myeloid leukemia: first-line drug of choice. Am J Hematol 91:59\u201366. https:\/\/doi.org\/10.1002\/ajh.24249","journal-title":"Am J Hematol"},{"key":"6093_CR42","unstructured":"Vivas W (2008) Manual PR\u00c1TICO DE HEMATOLOGIA, pp 1\u201333. http:\/\/www.aa.med.br\/upload\/biblioteca\/Manual%20de%20Hematologia.pdf"},{"key":"6093_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/tpj.2012.45","volume":"13","author":"SC Sim","year":"2013","unstructured":"Sim SC, Kacevska M, Ingelman-Sundberg M (2013) Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J 13:1\u201311","journal-title":"Pharmacogenomics J"},{"key":"6093_CR44","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000205823","volume":"83","author":"LAV Magno","year":"2009","unstructured":"Magno LAV, Talbot J, Talbot T et al (2009) Glutathione S-transferase variants in a Brazilian population. Pharmacology 83:231\u2013236. https:\/\/doi.org\/10.1159\/000205823","journal-title":"Pharmacology"},{"key":"6093_CR45","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000028396","volume":"61","author":"JD Hayes","year":"2000","unstructured":"Hayes JD, Strange RC (2000) Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 61:154\u2013166. https:\/\/doi.org\/10.1159\/000028396","journal-title":"Pharmacology"},{"key":"6093_CR46","first-page":"461","volume":"11","author":"K Sailaja","year":"2010","unstructured":"Sailaja K, Surekha D, Rao DN et al (2010) Association of the GSTP1 gene (Ile105Val) polymorphism with chronic myeloid leukemia. Asian Pacific J Cancer Prev 11:461\u2013464","journal-title":"Asian Pacific J Cancer Prev"},{"key":"6093_CR47","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.freeradbiomed.2011.04.013","volume":"51","author":"KD Tew","year":"2011","unstructured":"Tew KD, Manevich Y, Grek C et al (2011) The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancer. Free Radic Biol Med 51:299\u2013313. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2011.04.013","journal-title":"Free Radic Biol Med"},{"key":"6093_CR48","first-page":"160","volume":"17","author":"EFL Amaral","year":"2009","unstructured":"Amaral EFL (2009) Caracteriza\u00e7\u00e3o de Migrantes em Goi\u00e1s e Distrito Federal: 1980\u20132000. Teor E Soc 17:160\u2013185","journal-title":"Teor E Soc"},{"key":"6093_CR49","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1042\/bj2950313","volume":"295","author":"AA Fryer","year":"1993","unstructured":"Fryer AA, Zhao L, Alldersea J et al (1993) Use of site-directed mutagenesis of allele-specific PCR primers to identify the GSTM1 A, GSTM1 B, GSTM1 A,B and GSTM1 null polymorphisms at the glutathione S-transferase, GSTM1 locus. Biochem J 295:313\u2013315. https:\/\/doi.org\/10.1042\/bj2950313","journal-title":"Biochem J"},{"issue":"6","key":"6093_CR50","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1124\/mol.52.6.958","volume":"52","author":"RA Mclellan","year":"1997","unstructured":"Mclellan RA, Oscarson M, Alexandrie AK et al (1997) Characterization of a human glutathione S-Transferase \u03bc cluster containing a duplicated GSTM1 gene that causes ultrarapid enzyme activity. Mol Pharmacol 52(6):958\u2013965. https:\/\/doi.org\/10.1124\/mol.52.6.958","journal-title":"Mol Pharmacol"},{"key":"6093_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0006-291X(05)81248-3","volume":"180","author":"JL DeJong","year":"1991","unstructured":"DeJong JL, Mohandas T, Tu C-PD (1991) The human Hb (MU) class Gluthatione S-transferases are encoded by a dispersed gene family. Biochem Biophys Res Commun 180:15\u201322","journal-title":"Biochem Biophys Res Commun"},{"key":"6093_CR52","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1042\/bj2910041","volume":"291","author":"S Zhong","year":"1993","unstructured":"Zhong S, Spurr NK, Hayes JD, Wolf CR (1993) Deduced amino acid sequence, gene structure and chromosomal location of a novel human class Mu glutathione S-transferase, GSTM4. Biochem J 291:41\u201350","journal-title":"Biochem J"},{"key":"6093_CR53","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.freeradbiomed.2012.05.037","volume":"53","author":"W Wu","year":"2012","unstructured":"Wu W, Peden D, Diaz-Sanchez D (2012) Role of GSTM1 in resistance to lung inflammation. Free Radic Biol Med 53:721\u2013729","journal-title":"Free Radic Biol Med"},{"key":"6093_CR54","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.critrevonc.2015.08.020","volume":"97","author":"A Bennour","year":"2016","unstructured":"Bennour A, Saad A, Sennana H (2016) Chronic myeloid leukemia: relevance of cytogenetic and molecular assays. Crit Rev Oncol Hematol 97:263\u2013274. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.08.020","journal-title":"Crit Rev Oncol Hematol"},{"key":"6093_CR55","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","volume":"112","author":"D Marin","year":"2008","unstructured":"Marin D, Milojkovic D, Olavarria E et al (2008) European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112:4437\u20134444. https:\/\/doi.org\/10.1182\/blood-2008-06-162388","journal-title":"Blood"},{"key":"6093_CR56","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","volume":"118","author":"E Jabbour","year":"2011","unstructured":"Jabbour E, Kantarjian H, O\u2019Brien S et al (2011) The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 118:4541\u20134546. https:\/\/doi.org\/10.1182\/blood-2011-04-348110","journal-title":"Blood"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-020-06093-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-020-06093-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-020-06093-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T09:47:41Z","timestamp":1618998461000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-020-06093-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["6093"],"URL":"https:\/\/doi.org\/10.1007\/s11033-020-06093-z","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"20 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest or no financial conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Ethical Committee of Clinical Hospital of Federal University of Goi\u00e1s (protocol: 211\/2009).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patients signed their written informed consent, which was approved by the Ethical Committee of Clinical Hospital of Federal University of Goi\u00e1s (protocol: 211\/2009). The informed consent was obtained from the parent(s)\/legally autorized representative (LAR)\/guardians of the minors involved in the study. Patients or your parent(s)\/LAR\/guardians signed informed consent regarding publishing their data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}